⚙
AI-generated summary
by gemini-2.5-flash-lite, 2026-07-13
ⓘ
This review synthesizes evidence on prostaglandin's role in primary dysmenorrhea and demonstrates that NSAID therapy, when implemented as a complete clinical strategy, remains a rational first-line approach for prostaglandin-dominant cases.
⚙
AI-generated deep summary
by claude@2026-07, 2026-07-13
· read from full text
ⓘ
This paper reviews the role of prostaglandins in primary dysmenorrhea, describing a prostaglandin F2α/E2–dominant model in which increased mediators during menstruation drive uterine contractions, ischemia, and pain-pathway sensitization. It synthesizes evidence that anti-inflammatory (NSAID) therapy is pathogenetically justified in prostaglandin-dominant cases, emphasizing that effectiveness depends on early initiation, appropriate dosing, adherence, safety screening, and reassessment when response is inadequate, rather than evaluating NSAIDs as isolated drug effects. The paper also discusses the use of real-world data and AI-based analytics to flag poor responders and potential adverse drug reaction signals, while noting that if NSAID strategies fail, alternative mechanisms (e.g., secondary dysmenorrhea or central sensitization) should be considered. Relevance to endometriosis: it cites American College of Obstetricians and Gynecologists Committee Opinion No. 760 on dysmenorrhea and endometriosis in the adolescent, though the paper’s main focus is prostaglandins and anti-inflammatory therapy in primary dysmenorrhea rather than endometriosis itself.
Abstract
Primary dysmenorrhea is a recurrent menstrual pain syndrome occurring in the absence of identifiable pelvic pathology. Its most accepted pathophysiological model centers on increased endometrial production of prostaglandin F2α and prostaglandin E2 during menstruation. These mediators intensify uterine contractions, increase intrauterine pressure, reduce uterine blood flow, induce ischemia, and sensitize pain pathways. This article reviews the biological role of prostaglandins, the clinical rationale for NSAID therapy, timing and safety considerations, real-world effectiveness, pharmacovigilance, artificial intelligence, and personalized treatment strategies. The evidence synthesis shows that anti-inflammatory therapy is pathogenetically justified when primary dysmenorrhea is prostaglandin-dominant. However, treatment success depends on early initiation, correct dosing, patient education, safety screening, and reassessment when response is inadequate. Real-world data and AI-based analytics may help identify patients with poor response, detect adverse drug reaction signals, and improve clinical decision support. The article also discusses how Uzbekistan’s developing e-prescription and digital health systems may support safer NSAID use and national evidence generation. A central conclusion is that NSAID therapy should not be evaluated only as a drug effect, but as a complete clinical strategy that includes diagnosis, timing, adherence, contraindication screening, follow-up, and referral criteria. When this strategy is implemented correctly, prostaglandin inhibition remains a rational first-line approach. When it fails, clinicians should consider secondary dysmenorrhea, central sensitization, inadequate exposure, or non-prostaglandin mechanisms rather than repeating empirical analgesic escalation.
Full text
3,163 characters
· extracted from
oa-doi-fallback
· click to expand
THE ROLE OF PROSTAGLANDINS IN PRIMARY DYSMENORRHEA AND THE EFFECTIVENESS OF ANTI-INFLAMMATORY THERAPY
Authors/Creators
- 1. Termez University of Economics and Service
Description
Primary dysmenorrhea is a recurrent menstrual pain syndrome occurring in the absence of identifiable pelvic pathology. Its most accepted pathophysiological model centers on increased endometrial production of prostaglandin F2α and prostaglandin E2 during menstruation. These mediators intensify uterine contractions, increase intrauterine pressure, reduce uterine blood flow, induce ischemia, and sensitize pain pathways. This article reviews the biological role of prostaglandins, the clinical rationale for NSAID therapy, timing and safety considerations, real-world effectiveness, pharmacovigilance, artificial intelligence, and personalized treatment strategies.
The evidence synthesis shows that anti-inflammatory therapy is pathogenetically justified when primary dysmenorrhea is prostaglandin-dominant. However, treatment success depends on early initiation, correct dosing, patient education, safety screening, and reassessment when response is inadequate. Real-world data and AI-based analytics may help identify patients with poor response, detect adverse drug reaction signals, and improve clinical decision support. The article also discusses how Uzbekistan’s developing e-prescription and digital health systems may support safer NSAID use and national evidence generation.
A central conclusion is that NSAID therapy should not be evaluated only as a drug effect, but as a complete clinical strategy that includes diagnosis, timing, adherence, contraindication screening, follow-up, and referral criteria. When this strategy is implemented correctly, prostaglandin inhibition remains a rational first-line approach. When it fails, clinicians should consider secondary dysmenorrhea, central sensitization, inadequate exposure, or non-prostaglandin mechanisms rather than repeating empirical analgesic escalation.
Files
Qahramonov 149-162 NURSING.pdf
Files
(536.3 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:de672edd0b58b7706c7f322ae7d59145
|
536.3 kB | Preview Download |
Additional details
References
- 1. World Health Organization. Menstrual health. Geneva: WHO; 2026. Available from: https://www.who.int/news-room/fact-sheets/detail/menstrual-health
- 2. Itani R, Soubra L, Karout S, Rahme D, Karout L, Khojah HMJ. Primary dysmenorrhea: pathophysiology, diagnosis, and treatment updates. Korean J Fam Med. 2022;43(2):101-108. doi:10.4082/kjfm.21.0103
- 4. American College of Obstetricians and Gynecologists. Committee Opinion No. 760: Dysmenorrhea and endometriosis in the adolescent. Obstet Gynecol. 2018;132(6):e249-e258. doi:10.1097/AOG.0000000000002978
- 3. Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev. 2015;(7):CD001751. doi:10.1002/14651858.CD001751.pub3
- 4. American College of Obstetricians and Gynecologists. Committee Opinion No. 760: Dysmenorrhea and endometriosis in the adolescent. Obstet Gynecol. 2018;132(6):e249-e258. doi:10.1097/AOG.0000000000002978
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.